Connect with us
Finance Digest is a leading online platform for finance and business news, providing insights on banking, finance, technology, investing,trading, insurance, fintech, and more. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Research Reports

The Biologics Contract Manufacturing Demand Market is expected to grow by leaps and bounds In Upcoming Years. With digital convergence coming across as a pivot, the entire ecosystem inclusive of OEMs, providers, payers, and various other intermediaries is in the orbit. These value-based, end-user-centric models are the focal point. SMAC and IoT are being leveraged to build scalable connected digital platforms. This is the running trend and is expected to be in continuation in the forecast period.

Pharmaceuticals and biotechnology companies are outsourcing specific services from the early stages of drug development to biological contract manufacturing organizations to reduce drug manufacturing costs. Outsourcing increases drug manufacturing efficiency and facilitates flexible operational capabilities, which is expected to immensely boost biologics contract manufacturing demand. Rising prevalence of chronic and lifestyle diseases is also anticipated to propel biologics contract manufacturing demand. Besides, continuous focus by manufacturers toward adopting technologically-advanced systems to manufacture novel biologics is also expected to accelerate the demand for biologics contract manufacturing over the forecast period.

Get Sample Copy of this Report@

Global biologics contract manufacturing demand is expected to reach at 8 Mn liters (MnL) in 2030, exhibiting an impressive CAGR of over 17% during the forecast period (2020 – 2030).

Company Profiles:

  • BioXcellence (Boehringer Ingelheim GmbH)
  • Lonza Group AG
  • Samsung Biologics Co. Ltd.
  • Fujifilm Diosynth Biotechnologies (FUJIFILM Holdings)
  • AbbVie Contract Manufacturing (AbbVie Inc.)
  • WuXi Biologics (Cayman) Inc.
  • Patheon N.V. (Thermo Fisher Scientific Inc.)
  • Emergent BioSolutions Inc.
  • AGC Biologics
  • Ajinomoto Bio-Pharma (Ajinomoto Co., Inc.)
  • Avid Bioservices, Inc.
  • KBI Biopharma (JSR Life Sciences (JLS))
  • Catalent Inc.
  • Abzena Plc.

Get A Customized Scope To Match Your Need Ask An Expert –

Request for Methodology@

Key Takeaways from Biologics Contract Manufacturing Demand Study

  • Leading global CDMOs are focusing on expansion of their manufacturing capabilities with high flexibility and rapid operation capacity as biologics contract manufacturing demand is high. With the help of advanced single-use technologies, companies are able to cut batch manufacturing and cleaning time from 7 days to 1 day. This trend is expected to provide a competitive-edge to companies in terms of capacity, cost, convenience, and operational efficacy.
    • For instance, in Oct 2018, Thermo Fisher Scientific Inc. announced a US$ 50 million (€44 million) expansion at a CDMO plant in St Louis, Missouri, U.S., to add 16,000 L of single-use capacity due to extremely strong growth in demand for commercial biologic manufacturing. As per the company, the facility will be the largest outsourced single-use biologics site in North America.
  • With advancements in contract solutions, leading CDMOs are focusing on the expansion of their integrated capabilities from molecule-to-finished product. This trend is significant as the acceleration of development and speed to market is becoming more crucial for biopharmaceutical therapeutic developers.
  • Viral vector and vaccines contract development and manufacturing services are expected to gain significant traction due to the COVID-19 pandemic breakout and subsequent vaccine development programs.
    • For instance, in June 2020, AGC Biologics expanded its development capacities for pDNA services at the Heidelberg site, Germany, to meet the growing need for process development and manufacturing for plasmid DNA (pDNA).
  • Europe is expected to be the most lucrative region and with a revenue share of around one-third in global biologics contract manufacturing demand in 2020, owing to the presence of leading CDMO facilities in the region.

“Technological advancements to improve the manufacturing efficiency of biologics at low cost is expected to flourish market growth opportunities and provide a competitive advantage to market players in terms of innovation,” says a PMR analyst.

Access Full Report@

Doubling Industry Capacity by 2022-2023 amid COVID-19 Pandemic

The COVID-19 pandemic is becoming an industry changing milestone by providing opportunities to global CDMOs – small as well big CDMO companies. Local government and industry funds are being targeted toward rapid expansion of industry capacity in order to meet the unmet demand for vaccine development and commercialization amid the COVID-19 crisis.

For instance, in June 2020, Fujifilm Diosynth Biotechnologies announced the investment of 100 billion Yen (US$ 928 Million) to expand its large-scale biologics production facility in Denmark.

Expansion of Manufacturing Capacity – Imperative Strategy for Market Players

Key players involved in biologics contract manufacturing are looking forward to expand their manufacturing capacities to meet global demand. Leading companies are expanding their production capabilities and capacities to become the preferred choice for innovative biopharmaceutical companies and hold on to a strong position in the market.

For instance, in January 2019, Boehringer Ingelheim Biopharmaceuticals China expanded its commercial manufacturing capacities. The company installed an additional bioreactor, all needed utility, and infrastructure for GMP operations.

What Does the Report Cover?   

Persistence Market Research offers a unique perspective and actionable insights on biologics contract manufacturing demand in its latest study, presenting historical demand assessment of 2015 – 2019 and projections for 2020 – 2030, on the basis of platform (mammalian and microbial), application (commercial and clinical) product (monoclonal antibodies, recombinant proteins, vaccines, insulin, interferons, growth factors, and others), and therapeutic area (oncology, autoimmune disease, metabolic disease, ophthalmology, cardiovascular disease, infectious disease, neurology, respiratory disorders, and others), across seven key regions.

Related Reports:

Post Herpetic Neuralgia Treatment Market

Ankle Syndesmosis Treatment Devices Market

About Us: Persistence Market Research

Contact Us:

Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353

Japan Office: 1-2-1 Kinshi Arca Central Building
14/F Tokyo, 130-0013, Japan
Call 1-888-863-3700

Sales –
Website –

Continue Reading

Why pay for news and opinions when you can get them for free?

       Subscribe for free now!

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Recent Posts